Haemonetics (HAE) Q2 FY2027 earnings: revenue $358 million, up 9.3% on the year

Haemonetics Corp. (HAE) reported revenue of $358 million for Q2 FY2027, the quarter ended 26 September 2026, up 9.3% on the same quarter a year earlier. Net income was $46 million, up 19.7% on the year, and diluted earnings per share $1.00. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.

Revenue

$358 million

+9.3% on the year · +5.4% on the quarter

Q3 FY2025Q2 FY2027

Operating margin

21.0%

17.9% a year earlier

Q3 FY2025Q2 FY2027

Net income

$46 million

+19.7% on the year · +40.3% on the quarter

Q3 FY2025Q2 FY2027

Diluted EPS

$1.00

+23.5% on the year · +38.9% on the quarter

Q3 FY2025Q2 FY2027

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 4 raised, 1 lowered, 3 kept.

Revenue grew 9.3%, organic 10.0%: Second-quarter revenue was $357.8 million, up 9.3% reported and 10.0% organic. Currency reduced reported growth by 0.4 points and the liquid solution exit by 0.3 points.
Diluted EPS $1.00, adjusted $1.35: Diluted EPS was $1.00 against $0.81 a year earlier. Adjusted EPS was $1.35, and six-month adjusted EPS was $2.49 against $2.36.
Apheresis revenue up 12.6%: Apheresis revenue was $204.8 million, up 12.6% reported and 13.6% organic, against 6.0% organic growth in the first quarter.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q2 FY2027	Q1 FY2027	Q2 FY2026	On the quarter	On the year
Revenue	358	339	327	+5.4%	+9.3%
Cost of revenue	137	137	133	+0.2%	+3.2%
Gross profit	221	203	195	+8.9%	+13.4%
Gross margin	61.7%	59.8%	59.5%
Research and development	17.0	16.2	14.9	+5.1%	+14.5%
Selling, general and administrative	118	119	102	-0.5%	+16.5%
Operating income	75.1	57.5	58.5	+30.7%	+28.4%
Operating margin	21.0%	16.9%	17.9%
Pre-tax income	62.9	47.6	51.3	+32.1%	+22.6%
Income tax	16.6	14.6	12.6	+13.7%	+31.4%
Effective tax rate	26.3%	30.6%	24.6%
Net income	46.3	33.0	38.7	+40.3%	+19.7%
Net margin	12.9%	9.7%	11.8%
Diluted EPS	$1.00	$0.72	$0.81	+38.9%	+23.5%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q2 FY2027	Q1 FY2027	Q2 FY2026	On the quarter	On the year
Operating cash flow	128	52.3	111	+144.8%	+15.1%
Capital expenditure	14.8	7.9	5.0	+86.8%	+194.5%
Free cash flow	113	44.4	106	+155.1%	+6.6%
Free cash flow margin	31.7%	13.1%	32.5%
Cash from investing	-24.3	-22.2	-30.5
Cash from financing	-67.6	-51.5	-76.6
Depreciation and amortisation	27.8	27.1	28.3	+2.4%	-1.8%
Share-based compensation	10.2	9.3	7.6	+9.8%	+34.8%
Diluted shares, weighted	46m	46m	48m	+1.7%	-2.5%
Shares outstanding at period end	46m	45m	47m	+0.1%	-2.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q2 FY2027	Q1 FY2027	Q2 FY2026	On the quarter	On the year
Shareholders' equity	898	837	849	+7.3%	+5.8%
Debt	1,137	1,188	1,225	-4.3%	-7.2%
Other liabilities	375	340	368	+10.4%	+2.0%
Total liabilities and equity	2,411	2,365	2,442	+1.9%	-1.3%
Fixed assets	308	304	292	+1.4%	+5.3%
Goodwill	657	657	606	+0.0%	+8.4%
Intangible assets	426	435	428	-1.9%	-0.5%
Cash and equivalents	261	223	296	+16.7%	-12.0%
Receivables	225	216	207	+4.1%	+8.6%
Inventory	305	307	336	-0.6%	-9.3%
Other assets	229	224	276	+2.0%	-17.1%
Total assets	2,411	2,365	2,442	+1.9%	-1.3%

Questions

What was Haemonetics' revenue in Q2 FY2027?

Haemonetics (HAE) reported revenue of $358 million for Q2 FY2027, the quarter ended 26 September 2026, up 9.3% on the same quarter a year earlier.

How much did Haemonetics earn in Q2 FY2027?

Net income for Q2 FY2027 was $46 million, up 19.7% on the year, and diluted earnings per share $1.00.

When did Haemonetics report Q2 FY2027 results?

Haemonetics filed its 10-Q for the quarter ended 26 September 2026 with the SEC on 5 November 2026.

Quarterly results, the last 20 quarters

	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023 †	Q3 FY2023	Q4 FY2023 * †	Q1 FY2024 †	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025 †	Q3 FY2025	Q4 FY2025 * †	Q1 FY2026	Q2 FY2026	Q3 FY2026	Q4 FY2026 *	Q1 FY2027	Q2 FY2027
Revenue	260	265	261	297	305	304	311	318	336	343	336	346	349	331	321	327	339	346	339	358
Cost of revenue	121	129	119	140	147	148	144	148	158	167	161	158	155	138	129	133	137	148	137	137
Gross profit	139	136	142	158	159	156	167	171	178	176	175	187	194	193	192	195	202	198	203	221
Gross margin	53%	51%	54%	53%	52%	51%	54%	54%	53%	51%	52%	54%	56%	58%	60%	59%	60%	57%	60%	62%
R&D	10.0	13.2	10.9	10.9	12.7	15.6	12.6	12.7	13.3	15.9	14.4	14.1	15.8	18.3	16.3	14.9	14.2	14.4	16.2	17.0
SG&A	80.7	91.8	92.2	92.0	94.7	97.8	93.5	105	112	122	108	107	106	115	111	102	109	121	119	118
Operating income	35.7	19.2	30.8	46.7	43.3	35.3	53.7	35.3	46.0	29.9	39.8	51.7	59.0	71.3	53.9	58.5	67.4	-23.0	57.5	75.1
Operating margin	14%	7%	12%	16%	14%	12%	17%	11%	14%	9%	12%	15%	17%	22%	17%	18%	20%	-7%	17%	21%
Pre-tax income	31.4	15.3	25.5	41.1	42.2	32.6	51.6	32.8	44.0	23.4	46.7	44.7	49.9	70.7	45.2	51.3	60.0	-28.4	47.6	62.9
Tax rate	26%	36%	22%	19%	22%	10%	20%	24%	29%	13%	18%	24%	25%	18%	25%	25%	25%	n/a	31%	26%
Net income	23.2	9.7	19.9	33.2	32.9	29.4	41.0	24.9	31.2	20.4	38.4	33.8	37.5	58.0	34.0	38.7	44.7	-20.1	33.0	46.3
Net margin	9%	4%	8%	11%	11%	10%	13%	8%	9%	6%	11%	10%	11%	18%	11%	12%	13%	-6%	10%	13%
Diluted EPS	$0.45	$0.19	$0.38	$0.64	$0.64	$0.57	$0.80	$0.48	$0.61	$0.40	$0.74	$0.66	$0.74	$1.17	$0.70	$0.81	$0.95	-$0.44	$0.72	$1.00
Operating cash flow	62.4	68.0	42.0	87.0	64.4	79.6	19.1	99.1	-0.5	64.1	-27.4	48.8	43.8	117	17.4	111	93.6	70.9	52.3	128
Capital expenditure	26.7	35.1	45.5	36.0	16.8	11.9	7.7	24.7	22.3	9.7	5.7	9.4	8.5	15.6	3.8	5.0	6.3	17.7	7.9	14.8
Free cash flow	35.8	32.9	-3.5	51.1	47.6	67.7	11.4	74.5	-22.8	54.4	-33.1	39.4	35.2	101	13.6	106	87.2	53.3	44.4	113
Buybacks	0.0	n/a	n/a	n/a	0.0	n/a	n/a	n/a	0.0	n/a	n/a	n/a	0.0	n/a	n/a	n/a	0.0	n/a	n/a	n/a
Shares outstanding	51m	51m	51m	51m	50m	50m	51m	51m	51m	51m	51m	50m	50m	48m	48m	47m	47m	45m	45m	46m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 26 September 2026, filed 5 November 2026: the filing.